Browse studies

Find your next paid study

42 recruiting studies matching your filters

A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabol…

Metabolic Dysfunction-Associated SteatohepatitisNon-alcoholic Fatty Liver Disease

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06920043

Phase 1

Human Models of Selective Insulin Resistance: Diazoxide, Part I

The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resis…

HyperinsulinemiaInsulin ResistanceNon-Alcoholic Fatty Liver Disease+2 more

Estimated

~$10 – $6,250

Columbia UniversityNCT07403604

Observational

Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modific…

ObesityLiver DiseasesLiver Fibrosis+16 more

Estimated

~$10 – $7,500

Pichamol Jirapinyo, MD, MPHNCT06138821

Phase 1

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steato…

Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisMetabolic Dysfunction-associated Steatotic Liver Disease (MASLD)+1 more

Estimated

~$10 – $8,750

Corcept TherapeuticsNCT07553663

Phase 2

Clinical Trial of Oral Digoxin In NASH (CODIN)

Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment f…

NASHNAFLDMASH - Metabolic Dysfunction-Associated Steatohepatitis+5 more

Estimated

~$10 – $6,250

Yale UniversityNCT06588699

Phase 1

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease

This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepa…

Non-alcoholic Fatty Liver Disease

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07358546

Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population

In this initial investigator-initiated retrospective study, aim to analyze the enhanced liver fibrosis (ELF) scores in this high-risk population for NAFLD/nona…

Fatty Liver

Estimated

~$10 – $750

Methodist Health SystemNCT06225193

Observational

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease: A Pilot Study

This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterr…

Non-Alcoholic Fatty Liver Disease

Estimated

~$10 – $6,250

Weill Medical College of Cornell UniversityNCT05332613

Accurate Point of Care Liver Disease Diagnostics

This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in whi…

MASLDMASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)NAFLD+1 more

Estimated

~$10 – $750

University of California, San DiegoNCT07518784

Phase 2

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety o…

Non-Alcoholic Fatty Liver DiseaseNAFLDPediatric NAFLD

Estimated

~$10 – $7,500

Justin RyderNCT03867487

Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Study 2.0 - An FNIH Biomarkers Consortium Study

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance…

Metabolic Associated Fatty Liver DiseaseMetabolic Associated Steatotic Liver DiseaseCirrhosis, Liver+5 more

Estimated

~$10 – $675

Foundation for the National Institutes of HealthNCT07122700

Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases

The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are st…

Non-Alcoholic Steatohepatitis(NASH)Hepatitis CHepatitis B+5 more

Estimated

~$10 – $750

State University of New York at BuffaloNCT03025074